Compare Fifth Third Bancorp Common Stock (FITB) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fifth Third Bancorp Common Stock vs Natera Inc. Common Stock — how do they compare? Fifth Third Bancorp Common Stock trades at $49.75 (market cap $45.02B), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Fifth Third Bancorp Common Stock pays a 3.38% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fifth Third Bancorp Common Stock for 6 Days and Natera Inc. Common Stock for 0 Days on average.
| FITB | NTRA | |
|---|---|---|
Market Cap | $45.02B | $57.03B |
Volume | 6,867,388 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $59.37 | $425.64 |
52-Week Low | $40.36 | $179.42 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $62.91B | $56.18B |
Dividend Yield | 3.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fifth Third Bancorp (FITB) trades at $50.22, down 1.18% with bearish technical signals from moving averages. The stock shows solid fundamentals with a 22.36% net income margin and has beaten earnings expectations in two of the last three quarters. Recent news highlights the bank's innovation banking launch and Q3 guidance tracking at the high end of ranges post-Comerica conversion. Analyst consensus remains strongly positive with a $62.63 price target representing 25% upside potential.
FITB presents a compelling value opportunity with reasonable valuation multiples (P/E 16.91, P/B 1.41) and strong profitability metrics. Key risks include regulatory scrutiny of banking practices and integration challenges from the Comerica acquisition. The upcoming Q3 earnings report on October 19 will be crucial for validating the bank's growth trajectory and capital management strategy.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fifth Third Bancorp Common Stock
Fifth Third Bancorp provides retail and commercial banking, lending, payments, and wealth management services in the United States.
Read more on FITB →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
